Call for Abstracts - 3rd International Conference on HIV Treatment Adherence

March 17-18, 2008
Hyatt Regency Hotel, Jersey City, NJ
Adherence to medical treatment for HIV/AIDS is an essential determinant of treatment success or failure. Yet, we still have much to learn about measurement, determinants, and interventions for HIV treatment adherence — these are complex challenges that require multidisciplinary cooperation among providers, researchers, government agencies, and patients.

The goal of this conference is to provide an international forum for the presentation and discussion of state-of-the-science HIV treatment adherence research, as well as current behavioral and clinical perspectives in practicum. Our ultimate hope is that this dialogue translates into evidence-based implementation of approaches for real world clinical and community settings.

Objectives
After attending this conference, participants will be able to:

  • Identify successes and challenges in HIV treatment adherence in various settings and populations worldwide
  • Understand behavioral and clinical aspects of adherence that reflect a variety of HIV treatment team perspectives (e.g., patients, physicians, pharmacists, nurses, mental health professionals, adherence specialists)
  • Describe the relationships between adherence, pharmacokinetics, viral suppression, and resistance
  • Understand the implications of adherence for HIV prevention and public health
  • Identify adherence assessment tools and interventions that can be integrated into patient care, including in resource-limited settings

Abstract Submissions
All abstracts will be submitted online, a direct link can be found at www.iapac.org. All submitted abstracts will be considered for oral and poster presentations. Late-breaker abstracts will be considered for poster presentations only. All submitted abstracts should report information not previously published, or intended to be published, prior to March 17, 2008.

Oral abstract and poster presenters at the conference must pay their own travel and accommodation expenses, as well as the applicable registration fees. A discounted registration rate is available until November 30, 2007.

It is the responsibility of the presenting author to ensure accuracy of content, spelling, and presentation. Abstracts will be published as submitted, subject to reformatting that may be required by the Conference Organizers.

For further information, please visit:
http://www.iapac.org

About IAPAC
IAPAC (International Association of Physicians in AIDS Care) is recognized under the law of the United States of America as a 501(c)(3) not-for-profit organization. Working in partnership with the healthcare professions, business government, academe, and religious communities, IAPAC accomplishes its mission through a comprehensive program of education, policy and advocacy, direct technical assistance, and care provision initiatives spearheaded by physician members.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...

Scientific evidence to date on COVID-19 vaccine ef…

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe C...

How a plant virus could protect and save your lung…

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at...

COVID-19 nasal vaccine candidate effective at prev…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in develop...